Submitted by Geandra Rodrigues (geandrar@gmail.com) on 2018-03-26T19:37:06Z No. of bitstreams: 0 / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2018-03-27T14:03:04Z (GMT) No. of bitstreams: 0 / Made available in DSpace on 2018-03-27T14:03:04Z (GMT). No. of bitstreams: 0 Previous issue date: 2018-01-25 / A enurese é definida como incontinência urinária durante o sono que ocorre após os 5 anos de idade. A forma mais comum desta patologia é a enurese monossintomática, na qual não existem sintomas diurnos associados que indiquem disfunção miccional. A utilização da eletroestimulação nervosa transcutânea parassacral (ENTP) nas disfunções do trato urinário inferior já está bem difundida na literatura, no entanto seus efeitos na enurese monossintomática ainda precisam ser mais estudados. Objetivos: Avaliar a resposta clínica da ENTP associada à terapia comportamental em crianças com enurese primária monossintomática comparando ao tratamento comportamental. Material e Métodos: Estudo prospectivo, controlado e randomizado, no qual 72 crianças foram divididas em dois grupos: GC (uroterapia e estimulação elétrica placebo) e GE (uroterapia e ENTP). Em ambos os grupos, foram realizadas 20 sessões, três vezes por semana, durante vinte minutos cada, com 10Hz de frequência, 700μS de largura de pulso e intensidade determinada pelo paciente. Foram analisados os percentuais de noites secas 15 dias antes do tratamento (T0), após a realização da 20ª sessão (T1), 15 (T2), 30 (T3), 60 (T4) e 90 (T5) dias após o término das sessões. Resultados: Vinte crianças enuréticas, sendo 11 meninas (55%) com idade média de 9,09 ± 2,23 anos finalizaram o estudo. Os grupos eram semelhantes quanto o sexo (p>0,39). Não houve diferença na idade média entre os grupos. A média do percentual de noites secas do GE no T0 foi de 39,8%, no T1 de 53%, T2 de 58%, T3 59,2%, T4 58,2% e T5 63%, enquanto no GC esses percentuais eram de 24,4%, 37,3%, 33,4%, 33,2% e 34% respectivamente. A média do percentual de noites secas no GC foi de 32,7% e no GE 55,3% (p=0,046). Conclusão: A ENTP associada à terapia comportamental se mostrou mais eficaz que a terapia comportamental isolada no tratamento da enurese primária monossintomática. / Enuresis is characterized by nocturnal urinary incontinence and considered a disease after 5 years of age. The most common form of the disorder is monosymptomatic enuresis, when only nocturnal loss of urine is present. In non-monosymptomatic enuresis besides nocturnal loss of urine daytime lower urinary tract symptoms occur. It is believed that parassacral transcutaneous electrical neural stimulation (PTENS) has a physiological recondition effect redesigning synapses by neuronal plasticity. Its use in children with lower urinary tract dysfunction is well known, however, no study has evaluated its effects on monosymptomatic enuresis. Objectives: Evaluate the clinical response of PTENS in children with primary enuresis monosymptomatic comparing the behavioral treatment. Material and methods: 72 children were divided into two groups: CG (urotherapy and placebo electrical stimulation) and EG (urotherapy and ENTP). In both groups, 20 sessions were performed, three times a week, for twenty minutes each, with 10Hz of frequency, 700μS of pulse width and intensity determined by the patient. The percentages of dry nights 15 days before treatment (T0) were analyzed after the 20th session (T1), 15 (T2), 30 (T3), 60 (T4) and 90 (T5) days after the end of the sessions. Results: 20 children, 11 girls (55%) with a mean age of 9.09 ± 2.23 years completed the study. The groups were similar as for sex (p> 0.39). There was no difference in mean age between groups. Mean of the percentage of dry nights of EG at T0 was 39.8%, T1 at 53%, T2 at 58%, T3 at 59.2%, T4 at 58.2% and T5 at 63%, while in GC these percentages were 24.4%, 37.3%, 33.4%, 33.2% and 34%, respectively. The mean percentage of dry nights in the GC was 32.7% and in the GE 55.3% (p = 0.046). Conclusion: PTENS associated with behavioral therapy was shown to be effective in the treatment of monosymptomatic primary enuresis.